Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

AML

Roche Basel Switzerland

Roche files Tecentriq/Avastin combo in liver cancer

First treatment in over a decade to improve overall survival

- PMLiVE

EU grants conditional approval to Roche’s lymphoma drug Polivy

Drug demonstrated a 40% complete response rate in trial

- PMLiVE

AbbVie lauds head-to-head win for Skyrizi versus Cosentyx

Outperformed rival across all primary and secondary endpoints

Roche Basel Switzerland

Roche and Illumina partner on genomics for cancer diagnostics

Will leverage genomics system to match optimal cancer treatment

- PMLiVE

AbbVie creates new aesthetics division amid Allergan takeover

New separate business unit will operate own R&D functions

- PMLiVE

NICE knocks back Roche’s Tecentriq for small cell lung cancer

Insufficient evidence to approve use in SCLC on the NHS

- PMLiVE

Allergan gets FDA nod for first oral CGRP drug for migraine

Extended use into acute treatment of migraine

Roche Basel Switzerland

Roche pays $1.15bn for Sarepta’s Duchenne gene therapy

Pens another gene therapy deal following takeover of Spark Therapeutics

- PMLiVE

AbbVie’s JAK inhibitor Rinvoq approved in EU for rheumatoid arthritis

Continued expansion for next-generation immunology drug

Roche Basel Switzerland

Roche to close $4.3bn Spark deal after FTC clearance

Comes on the heels of CMA green light

- PMLiVE

UK’s CMA clears Roche’s $4.3bn takeover of Spark

Roche first announced deal in February

- PMLiVE

Roche’s Tecentriq combo scores in first-line melanoma

Plans to file treatment with health authorities on strength of data

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links